Vyskočilová Markéta, Svojanovský Jan, Blaštíková Jana, Dvořáková Gabriela, Souček Miroslav
Vnitr Lek. 2015 Feb;61(2):166-72.
Calcific uremic arteriolopathy or calciphylaxis is a rare disorder characterized by systemic medial calcification of arterioles that leads to ischemia and subcutaneous necrosis. It most commonly occurs in patients with end-stage renal disease who are on haemodialysis or who have received a renal transplant. Calciphylaxis is dangerous by its fast progression into tissue necrosis, difficult healing process and a great risk of secondary infection which is the most common cause of death in this condition. The reported mortality rates are as high as 60-80 % in a couple of months once it is diagnosed. The key to successful treatment of calciphylaxis is fast diagnosing of the disease and appropriate treatment management. On the examples of three patients from our haemodialysis centre we demonstrate typical clinical manifestation of calciphylaxis and its treatment, which requires close patient-medical staff cooperation. The basic principle of treatment of all our patients was normalization of calcium-phosphate metabolism and secondary hyperparathyroidism. Sodium thiosulfate had been administered to all patients at the end of haemodialysis session. The wound care played another major role with gentle debridement and intensive local care. After five to six months the skin defects resolved in the first patient, partially resolved in the second patient and deteriorated in the third patient. We have observed no side effects of sodium thiosulfate application.
钙化性尿毒症小动脉病或钙化防御是一种罕见的疾病,其特征是小动脉的系统性中层钙化,导致局部缺血和皮下坏死。它最常发生在接受血液透析或接受过肾移植的终末期肾病患者中。钙化防御因其迅速发展为组织坏死、愈合过程困难以及继发感染风险高而危险,继发感染是这种情况下最常见的死亡原因。据报道,一旦确诊,几个月内死亡率高达60%-80%。成功治疗钙化防御的关键是快速诊断疾病并进行适当的治疗管理。以我们血液透析中心的三名患者为例,我们展示了钙化防御的典型临床表现及其治疗方法,这需要患者与医护人员密切合作。我们所有患者的基本治疗原则是使钙磷代谢和继发性甲状旁腺功能亢进正常化。在血液透析结束时,所有患者均接受了硫代硫酸钠治疗。伤口护理起着另一个主要作用,包括轻柔清创和强化局部护理。五到六个月后,第一名患者的皮肤缺损得到解决,第二名患者部分得到解决,第三名患者病情恶化。我们未观察到硫代硫酸钠应用的副作用。